Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus (Q44193427)

30 November 2017

title

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus (English)

1 reference

30 November 2017

1 reference

1 reference

3

Santica M Marcovina

1 reference

30 November 2017

Martin I Freed

1

1 reference

30 November 2017

Robert Ratner

2

1 reference

30 November 2017

Margaret M Kreider

4

1 reference

30 November 2017

Nandita Biswas

5

1 reference

30 November 2017

Beth R Cohen

6

1 reference

30 November 2017

John D Brunzell

7

1 reference

30 November 2017

Rosiglitazone Study 108 investigators

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Cardiology

30 November 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 November 2017

volume

90

1 reference

30 November 2017

issue

9

1 reference

30 November 2017

page(s)

947-952

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Enzymatic methods for quantification of lipoprotein lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

The role of small, dense low density lipoprotein (LDL): a new look

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Effect of hepatic lipase on LDL in normal men and those with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Potential interaction between troglitazone and atorvastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902659-0

10.1016/S0002-9149(02)02659-0

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference